Posted by Iain Butler, Partner
Royds Withy King advises on a £7.5m investment for Oxford Genetics
Corporate lawyers from UK Top 100 law firm Royds Withy King in Oxford have advised Oxford Genetics, a leader in innovative synthetic biology-based technologies, on a £7.5 million investment into its operations in the US and the UK.
Jennifer Sampson and Tony Roberts, from Royds Withy King’s Corporate and Commercial team, advised Ryan Cawood, CEO of Oxford Genetics, and his team on the terms of the investment agreement with Mercia Technologies PLC, an existing investor, and new investors Invesco Perpetual.
Jennifer Sampson, corporate lawyer at Royds Withy King, said: “We are delighted to have advised on the deal that will help our client to innovate in cell and gene therapy, fund a new office in Boston and extend its UK facilities. Oxfordshire is a hub for life sciences businesses. It has been a fantastic opportunity to facilitate a substantial investment into a highly innovative business and see sector growth in the region. We wish Ryan and his team all the best in their next phase of development.”
Commenting on the deal, Ryan Cawood said: “Working with Royds Withy King on this deal was great, they supported Oxford Genetics throughout and helped us negotiate this strategic investment that will allow us to significantly expand our operations. Having a lawyer who responded to emails at 6am in the morning of our closing was pretty reassuring! We certainly look forward to working with Jennifer and the team again.”
Royds Withy King, which has a dedicated team with life sciences sector expertise, is also supporting a series of initiatives at Harwell Campus as well as events on innovation in science and technology, run by The Bessemer Society.
Corporate & Commercial
Keeping you informed about Corporate & Commercial news, events and opinion.